Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15509800 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kim YJ, et al. (2004) Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol 24, 9986-99 15509800
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human

Y783-p - PLCG1 (human)
Orthologous residues
PLCG1 (human): Y783‑p, PLCG1 iso2 (human): Y783‑p, PLCG1 (mouse): Y783‑p, PLCG1 (rat): Y783‑p, PLCG1 (cow): Y783‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
LY294002 anti-IgM inhibit treatment-induced increase

Y753-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y753‑p, PLCG2 (mouse): Y753‑p, PLCG2 (rat): Y753‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), Null-TV1, platelet-blood, RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Btk (human) inhibition of upstream enzyme, antisense inhibition of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
vanadate increase
convulxin increase
anti-CD3 increase
anti-IgM increase
vanadate anti-IgM augment treatment-induced increase
PP1 anti-IgM inhibit treatment-induced increase
LY294002 anti-IgM inhibit treatment-induced increase
LFM-A13 anti-IgM inhibit treatment-induced increase
bisindolylmaleimide anti-IgM augment treatment-induced increase
phorbol ester anti-IgM inhibit treatment-induced increase

Y759-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y759‑p, PLCG2 (mouse): Y759‑p, PLCG2 (rat): Y759‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), Null-TV1, platelet-blood, RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Btk (human) inhibition of upstream enzyme, antisense inhibition of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
vanadate increase
convulxin increase
anti-CD3 increase
anti-IgM increase
PP1 anti-IgM inhibit treatment-induced increase
LY294002 anti-IgM inhibit treatment-induced increase
wortmannin anti-IgM inhibit treatment-induced increase
bisindolylmaleimide anti-IgM augment treatment-induced increase
phorbol ester anti-IgM inhibit treatment-induced increase
vanadate anti-IgM augment treatment-induced increase
LFM-A13 anti-IgM inhibit treatment-induced increase
anti-CD19 anti-IgM no effect upon treatment-induced increase
anti-CD19 no change compared to control

Y1197-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y1197‑p, PLCG2 (mouse): Y1197‑p, PLCG2 (rat): Y1197‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  Null-TV1, RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF no change compared to control
convulxin no change compared to control
anti-IgM no change compared to control
anti-CD3 no change compared to control
vanadate increase

Y1217-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y1217‑p, PLCG2 (mouse): Y1217‑p, PLCG2 (rat): Y1217‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  Null-TV1, RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF no change compared to control
convulxin no change compared to control
anti-CD3 no change compared to control
vanadate increase
anti-IgM increase
PP1 anti-IgM inhibit treatment-induced increase
LY294002 anti-IgM no effect upon treatment-induced increase
wortmannin anti-IgM no effect upon treatment-induced increase
bisindolylmaleimide anti-IgM no effect upon treatment-induced increase
LFM-A13 anti-IgM no effect upon treatment-induced increase
phorbol ester anti-IgM no effect upon treatment-induced increase
vanadate anti-IgM no effect upon treatment-induced increase

Y753-p - PLCG2 (mouse)
Orthologous residues
PLCG2 (human): Y753‑p, PLCG2 (mouse): Y753‑p, PLCG2 (rat): Y753‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  B lymphocyte-spleen
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
LY294002 anti-IgM inhibit treatment-induced increase
wortmannin anti-IgM inhibit treatment-induced increase

Y759-p - PLCG2 (mouse)
Orthologous residues
PLCG2 (human): Y759‑p, PLCG2 (mouse): Y759‑p, PLCG2 (rat): Y759‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  B lymphocyte-spleen
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
LY294002 anti-IgM inhibit treatment-induced increase
wortmannin anti-IgM inhibit treatment-induced increase

Y1217-p - PLCG2 (mouse)
Orthologous residues
PLCG2 (human): Y1217‑p, PLCG2 (mouse): Y1217‑p, PLCG2 (rat): Y1217‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  B lymphocyte-spleen
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
LY294002 anti-IgM no effect upon treatment-induced increase
wortmannin anti-IgM no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.